Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure

Heart. 1999 September; 82(3): 352–356.

PMCID: PMC1729194

D Murdoch, E Rooney, H Dargie, D Shapiro, J Morton, and J McMurray

Department of Cardiology, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK. Email: drm2x/at/udcf.gla.ac.uk

This article has been cited by other articles in PMC.

Abstract

BACKGROUND—Cardiac cachexia is a syndrome of generalised wasting which caries a poor prognosis and is associated with raised plasma concentrations of tumour necrosis factor α (TNFα). TNFα increases secretion of leptin, a hormone which decreases food intake and increases energy expenditure.
OBJECTIVE—To determine whether an inappropriate increase in plasma leptin concentration contributes to the cachexia of chronic heart failure.
DESIGN—Retrospective case-control study.
SETTING—Tertiary referral cardiology unit.
PATIENTS—110 human subjects comprising 29 cachectic chronic heart failure patients, 22 non-cachectic chronic heart failure patients, 33 patients with ischaemic heart disease but normal ventricular function, and 26 healthy controls.
INTERVENTIONS—Measurement of: body fat content by skinfold thickness (cachectic males < 27%, females < 29%); plasma leptin, TNFα, and noradrenaline (norepinephrine); central haemodynamics in chronic heart failure patients at right heart catheterisation.
MAIN OUTCOME MEASURES—Plasma leptin concentration corrected for body fat content, plasma TNFα and noradrenaline concentration, and central haemodynamics.
RESULTS—Mean (SEM) plasma leptin concentrations were: 6.2 (0.6) ng/ml (cachectic heart failure), 16.9 (3.6) ng/ml (non-cachectic heart failure), 16.8 (3.0) ng/ml (ischaemic heart disease), and 18.3(3.5) ng/ml (control) (p < 0.001 for cachectic heart failure v all other groups). Plasma leptin concentration remained significantly lower in the cachectic heart failure group even after correcting for body fat content and in spite of significantly increased TNFα concentrations. Thus plasma leptin was inappropriately low in cachectic chronic heart failure in the face of a recognised stimulus to its secretion. There was no significant correlation between plasma leptin, New York Heart Association class, ejection fraction, or any haemodynamic indices.
CONCLUSIONS—Leptin does not contribute to the cachexia of chronic heart failure. One or more leptin suppressing mechanisms may operate in this syndrome—for example, the sympathetic nervous system.

Keywords: heart failure; cytokines; leptin; cachexia

Full Text

The Full Text of this article is available as a PDF (96K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Zhang, Y; Proenca, R; Maffei, M; Barone, M; Leopold, L; Friedman, JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994 Dec 1;372(6505):425–432. [PubMed]
Considine, RV; Sinha, MK; Heiman, ML; Kriauciunas, A; Stephens, TW; Nyce, MR; Ohannesian, JP; Marco, CC; McKee, LJ; Bauer, TL, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996 Feb 1;334(5):292–295. [PubMed]
Banks, WA; Kastin, AJ; Huang, W; Jaspan, JB; Maness, LM. Leptin enters the brain by a saturable system independent of insulin. Peptides. 1996;17(2):305–311. [PubMed]
Maffei, M; Stoffel, M; Barone, M; Moon, B; Dammerman, M; Ravussin, E; Bogardus, C; Ludwig, DS; Flier, JS; Talley, M, et al. Absence of mutations in the human OB gene in obese/diabetic subjects. Diabetes. 1996 May;45(5):679–682. [PubMed]
Considine, RV; Considine, EL; Williams, CJ; Nyce, MR; Magosin, SA; Bauer, TL; Rosato, EL; Colberg, J; Caro, JF. Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity. J Clin Invest. 1995 Jun;95(6):2986–2988. [PubMed]
Maffei, M; Halaas, J; Ravussin, E; Pratley, RE; Lee, GH; Zhang, Y; Fei, H; Kim, S; Lallone, R; Ranganathan, S, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med. 1995 Nov;1(11):1155–1161. [PubMed]
McMurray, J; Abdullah, I; Dargie, HJ; Shapiro, D. Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J. 1991 Nov;66(5):356–358. [PubMed]
Levine, B; Kalman, J; Mayer, L; Fillit, HM; Packer, M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990 Jul 26;323(4):236–241. [PubMed]
Zhao, SP; Zeng, LH. Elevated plasma levels of tumor necrosis factor in chronic heart failure with cachexia. Int J Cardiol. 1997 Feb;58(3):257–261. [PubMed]
Sarraf, P; Frederich, RC; Turner, EM; Ma, G; Jaskowiak, NT; Rivet, DJ, 3rd; Flier, JS; Lowell, BB; Fraker, DL; Alexander, HR. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J Exp Med. 1997 Jan 6;185(1):171–175. [PubMed]
Grunfeld, C; Zhao, C; Fuller, J; Pollack, A; Moser, A; Friedman, J; Feingold, KR. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest. 1996 May 1;97(9):2152–2157. [PubMed]
Zumbach, MS; Boehme, MW; Wahl, P; Stremmel, W; Ziegler, R; Nawroth, PP. Tumor necrosis factor increases serum leptin levels in humans. J Clin Endocrinol Metab. 1997 Dec;82(12):4080–4082. [PubMed]
Simons, JP; Schols, AM; Campfield, LA; Wouters, EF; Saris, WH. Plasma concentration of total leptin and human lung-cancer-associated cachexia. Clin Sci (Lond). 1997 Sep;93(3):273–277. [PubMed]
Durnin, JV; Rahaman, MM. The assessment of the amount of fat in the human body from measurements of skinfold thickness. Br J Nutr. 1967 Aug;21(3):681–689. [PubMed]
Durnin, JV; Womersley, J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr. 1974 Jul;32(1):77–97. [PubMed]
Goldstein, DS; Feuerstein, G; Izzo, JL, Jr; Kopin, IJ; Keiser, HR. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sci. 1981 Feb 2;28(5):467–475. [PubMed]
Wallenstein, S; Zucker, CL; Fleiss, JL. Some statistical methods useful in circulation research. Circ Res. 1980 Jul;47(1):1–9. [PubMed]
Anand, IS; Ferrari, R; Kalra, GS; Wahi, PL; Poole-Wilson, PA; Harris, PC. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation. 1989 Aug;80(2):299–305. [PubMed]
Swan, JW; Walton, C; Godsland, IF; Clark, AL; Coats, AJ; Oliver, MF. Insulin resistance in chronic heart failure. Eur Heart J. 1994 Nov;15(11):1528–1532. [PubMed]
Anker, SD; Chua, TP; Ponikowski, P; Harrington, D; Swan, JW; Kox, WJ; Poole-Wilson, PA; Coats, AJ. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997 Jul 15;96(2):526–534. [PubMed]
Cumin, F; Baum, HP; Levens, N. Leptin is cleared from the circulation primarily by the kidney. Int J Obes Relat Metab Disord. 1996 Dec;20(12):1120–1126. [PubMed]
Esler, M; Vaz, M; Collier, G; Nestel, P; Jennings, G; Kaye, D; Seals, D; Lambert, G. Leptin in human plasma is derived in part from the brain, and cleared by the kidneys. Lancet. 1998 Mar 21;351(9106):879–879. [PubMed]
Iida, M; Murakami, T; Yamada, M; Sei, M; Kuwajima, M; Mizuno, A; Noma, Y; Aono, T; Shima, K. Hyperleptinemia in chronic renal failure. Horm Metab Res. 1996 Dec;28(12):724–727. [PubMed]
Ansari, A. Syndromes of cardiac cachexia and the cachectic heart: current perspective. Prog Cardiovasc Dis. 1987 30(1):45–60.Jul–Aug; [PubMed]
Morrison, WL; Edwards, RH. Cardiac cachexia. BMJ. 1991 Feb 9;302(6772):301–302. [PubMed]
Riley, M; Elborn, JS; McKane, WR; Bell, N; Stanford, CF; Nicholls, DP. Resting energy expenditure in chronic cardiac failure. Clin Sci (Lond). 1991 Jun;80(6):633–639. [PubMed]
Poehlman, ET; Scheffers, J; Gottlieb, SS; Fisher, ML; Vaitekevicius, P. Increased resting metabolic rate in patients with congestive heart failure. Ann Intern Med. 1994 Dec 1;121(11):860–862. [PubMed]
Trayhurn, P; Duncan, JS; Rayner, DV; Hardie, LJ. Rapid inhibition of ob gene expression and circulating leptin levels in lean mice by the beta 3-adrenoceptor agonists BRL 35135A and ZD2079. Biochem Biophys Res Commun. 1996 Nov 12;228(2):605–610. [PubMed]
Gettys, TW; Harkness, PJ; Watson, PM. The beta 3-adrenergic receptor inhibits insulin-stimulated leptin secretion from isolated rat adipocytes. Endocrinology. 1996 Sep;137(9):4054–4057. [PubMed]
Kosaki, A; Yamada, K; Kuzuya, H. Reduced expression of the leptin gene (ob) by catecholamine through a G(S) protein-coupled pathway in 3T3-L1 adipocytes. Diabetes. 1996 Dec;45(12):1744–1749. [PubMed]
Trayhurn, P; Duncan, JS; Rayner, DV. Acute cold-induced suppression of ob (obese) gene expression in white adipose tissue of mice: mediation by the sympathetic system. Biochem J. 1995 Nov 1;311 (:729–733. [PubMed]
Donahoo, WT; Jensen, DR; Yost, TJ; Eckel, RH. Isoproterenol and somatostatin decrease plasma leptin in humans: a novel mechanism regulating leptin secretion. J Clin Endocrinol Metab. 1997 Dec;82(12):4139–4143. [PubMed]
Pelleymounter, MA; Cullen, MJ; Baker, MB; Hecht, R; Winters, D; Boone, T; Collins, F. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 1995 Jul 28;269(5223):540–543. [PubMed]